Nilotinib Granted FDA Approval for Pediatric CML
Based on data from 2 clinical trials, nilotinib (Tasigna) has been approved by the FDA for the first- and 2nd-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!